Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mödling – page 58

863 clinical trials in Mödling, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mödling at a glance
863
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

863 trials in Mödling

Open in trial search

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Study on the Effect of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Vienna

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Celgene Corp.

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Gastric cancer+1

Not recruiting

Study on the Safety and Activity of S095029 and Pembrolizumab for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Neoplasm

Not recruiting

Study of Avapritinib for Children with Solid Tumors Linked to KIT or PDGFRA Signaling

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Myasthenia gravis

Not recruiting

Study on the Safety and Effectiveness of Gefurulimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gefurulimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mödling

What the registry says about research in the country

01 Diabetes & Cardiovascular Health

Clinical research focusing on Type 2 Diabetes Mellitus patients, exploring innovative approaches to prevent heart disease. The trials evaluate the effectiveness of intensive treatment using RAS-antagonists and beta-blockers compared to standard therapy.

  • Heart Disease Prevention
  • Diabetes Management
  • Cardiac Event Reduction

Studies utilize specialized biomarkers like NT-proBNP to guide treatment strategies and reduce hospitalization rates.

02 Stroke Prevention Research

Investigating advanced treatments for ischemic stroke prevention, with particular focus on patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-Stroke Care
  • Blood Clot Prevention
  • Antiplatelet Therapy

The research evaluates the efficacy of asundexian, an oral FXIa inhibitor, in combination with standard antiplatelet therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.